Published in Medical Letter on the CDC and FDA, July 24th, 2005
The report provides an in-depth overview of the company's upcoming phase 1/2 clinical trials, and past clinical trials, for its drug candidate AMZ 0026, the HIV and AIDS landscape and market opportunity, the difference between, and importance of, antiretrovirals and immune modulators, as well as the investment opportunity Amazon presents.
The report is available...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.